Multiple myeloma: patient outcomes in real‐world practice
Open accessAbstract
Summary: With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first‐line therapy was 6 months, followed by a median treatment‐free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician‐judged. Toxicities and co‐morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real‐world data provide an insight into patient outcomes and treatment decisions being made in clinical practice.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most patients with multiple myeloma have a relapse after standard treatment, and outcomes worsen with each subsequent line of therapy.
“outcomes worsen with each subsequent line of therapy. 3-5”
From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 25
- Acaster, S., Gaugris, S., Velikova, G., Yong, K. & Lloyd, A.J. (2013) Impact of the treatment‐free interval on health‐related quality of life in patients with multiple myeloma: a UK cross‐sectional survey. Supportive Care in Cancer, 21, 599– 607. 22886429
- Birgegard, G., Gascon, P. & Ludwig, H. (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. European Journal of Haematology, 77, 378– 386. 17044835 PMC1618958
- Carpenter, J. & Bithell, J. (2000) Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Statistics in Medicine, 19, 1141– 1164. 10797513
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123– 2132. 18032762
- Durie, B.G.M. (2011) Multiple Myeloma, Cancer of the Bone Marrow: Concise Review of the Disease and Treatment Options. 2015 International Myeloma Foundation, North Hollywood, CA.
- Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842– 854. 1182674
- Eslick, R. & Talaulikar, D. (2013) Multiple myeloma: from diagnosis to treatment. Australian Family Physician, 42, 684– 688. 24130968
- Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet‐Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412– 3420. 15809451
- Kumar, S.K., Therneau, T.M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Lust, J.A., Larson, D.R., Kyle, R.A. & Greipp, P.R. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proceedings, 79, 867– 874. 15244382
- Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21– 33. 12528874
- van der Laan, M.J. & Dudoit, S. (2003) Unified cross‐validation methodology for selection among estimators and a general cross‐validated adaptive epsilon‐net estimator: finite sample oracle inequalities and examples. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 130. Vol. 2015.
- Lonial, S. & Anderson, K.C. (2014) Association of response endpoints with survival outcomes in multiple myeloma. Leukemia, 28, 258– 268. 23868105 PMC3918869
- Muhlbacher, A.C. & Nubling, M. (2011) Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. The European Journal of Health Economics, 12, 193– 203. 20107856
- Muhlbacher, A.C., Lincke, H.J. & Nubling, M. (2008) Evaluating patients' preferences for multiple myeloma therapy, a Discrete‐Choice‐Experiment. Psycho‐Social Medicine, 5, 1– 10. Doc10. PMC2736517 19742282
- Offidani, M., Corvatta, L., Maracci, L., Liberati, A.M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti, A., Cellini, C., Malerba, L., Mele, A., Andriani, A., Galimberti, S., Mondello, P., Pulini, S., Coppetelli, U., Fraticelli, P., Olivieri, A. & Leoni, P. (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed‐refractory multiple myeloma: a phase II study. Blood Cancer Journal, 3, e162. 24270324 PMC3880441
- Raab, M.S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McGuire, S., Karlin, L., Mateos, M.‐V., Schoen, P. & Yong, K. (2015) Multiple myeloma management: practice patterns across Europe. Haematologica, 100, 251. 27291397
- Raab, M.S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M.N., Schoen, P. & Yong, K. (2016) Multiple myeloma: practice patterns across Europe. British Journal of Haematology, 175, 66– 76. 27291397
- van Rhee, F., Giralt, S. & Barlogie, B. (2014) The future of autologous stem cell transplantation in myeloma. Blood, 124, 328– 333. 24894774 PMC4102706
- Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San‐Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high‐dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487– 2498. 15958804
- Richardson, P.G., Moreau, P., Laubach, J.P., Gupta, N., Hui, A.M., Anderson, K.C., San Miguel, J.F. & Kumar, S. (2015) The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology, 11, 1153– 1168. 25832873
- Rifkin, R.M., Abonour, R., Terebelo, H., Shah, J.J., Gasparetto, C., Hardin, J., Srinivasan, S., Ricafort, R., Nagarwala, Y. & Durie, B.G. (2015) Connect MM Registry: the importance of establishing baseline disease characteristics. Clinical Lymphoma, Myeloma and Leukemia, 15, 368– 376. 25617035
- San Miguel, J., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez‐Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M. (2013) Pomalidomide plus low‐dose dexamethasone versus high‐dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM‐003): a randomised, open‐label, phase 3 trial. The Lancet. Oncology, 14, 1055– 1066. 24007748
- San‐Miguel, J.F., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Gunther, A., Nakorn, T.N., Siritanaratkul, N., Corradini, P., Chuncharunee, S., Lee, J.J., Schlossman, R.L., Shelekhova, T., Yong, K., Tan, D., Numbenjapon, T., Cavenagh, J.D., Hou, J., LeBlanc, R., Nahi, H., Qiu, L., Salwender, H., Pulini, S., Moreau, P., Warzocha, K., White, D., Blade, J., Chen, W., de la Rubia, J., Gimsing, P., Lonial, S., Kaufman, J.L., Ocio, E.M., Veskovski, L., Sohn, S.K., Wang, M.C., Lee, J.H., Einsele, H., Sopala, M., Corrado, C., Bengoudifa, B.R., Binlich, F. & Richardson, P.G. (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double‐blind phase 3 trial. The Lancet. Oncology, 15, 1195– 1206. 25242045
- Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova‐Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San‐Miguel, J.F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., Ben‐Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P. & Palumbo, A. (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 372, 142– 152.25482145
- Torimoto, Y., Shindo, M., Ikuta, K. & Kohgo, Y. (2015) Current therapeutic strategies for multiple myeloma. International Journal of Clinical Oncology, 20, 423– 430. 25855312
Cited by
Sorted by citations
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works
Self-citationCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827 · see citing works
Self-citationIsatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284 · see citing works
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166 · see citing works
Fonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127 · see citing works
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48 · see citing works
Self-citationSiegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46 · see citing works
Dhanasiri, S., Hollier-Hann, G., Stothard, C., Dhanda, D. S., Davies, F. E., & Rodriguez-Otero, P. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.09.013 · Cited by 22 · see citing works
- Authors
- Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., Schoen, P., & Cavo, M.
- Affiliations
- University College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Kantonsspital St. Gallen (CH)
- Kantar Health Montrouge France
- Amgen (Switzerland) (CH)
- Hôpital Lyon Sud (FR)
- Department of Hematology University Hospital of Salamanca Salamanca Spain
- Heidelberg University (DE)
- 'Seràgnoli' Institute of Hematology and Medical Oncology Bologna University School of Medicine Bologna Italy
- Corresponding author
- Yong, Kwee
- ORCID
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2016-07-13
- Volume
- 175
- Issue
- 2
- Pages
- 252-264
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- PMC
- PMC5096152
- OpenAlex
- W2460376887
- Cited by
- 326
- References
- 3
- Citations by year
- 2026: 21 · 2025: 36 · 2024: 37 · 2023: 46 · 2022: 49 · 2021: 42 · 2020: 40 · 2019: 27 · 2018: 18 · 2017: 7 · 2016: 2
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- British Journal of Haematology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, real-world outcomes, treatment duration, treatment lines, depth of response, time to progression, treatment discontinuation, treatment toxicity, comorbidities, bone pain
- MeSH terms
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cross-Sectional Studies, Europe, Female, Humans, Male, Middle Aged, Multiple Myeloma, Phenotype, Physicians, Retrospective Studies, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Disease Progression, Disease Management, Health Care Surveys
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
